Who are Incobotulinumtoxin A's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Botulinum neurotoxin (BTX), Botulinum toxin A 150u, Botulinum Toxin A (Botox ), botulinum type a, intra-rectal botulinum toxin injections, Botulinum Toxin Type A Injection [HG102].

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/incobotulinumtoxin-a.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Incobotulinumtoxin A — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Incobotulinumtoxin A (Incobotulinumtoxin A) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neurotoxin. Area: Neurology.

phase 2 Neurotoxin SNARE proteins Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Incobotulinumtoxin A (Incobotulinumtoxin A) — Ulthera, Inc. Incobotulinumtoxin A is a neurotoxin that blocks the release of acetylcholine at neuromuscular junctions, leading to temporary muscle paralysis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Incobotulinumtoxin A TARGET	Incobotulinumtoxin A	Ulthera, Inc	phase 2	Neurotoxin	SNARE proteins
Botulinum neurotoxin (BTX)	Botulinum neurotoxin (BTX)	The University of Texas Health Science Center, Houston	marketed	Neurotoxin; acetylcholine release inhibitor	SNARE proteins (SNAP-25, VAMP, syntaxin)
Botulinum toxin A 150u	Botulinum toxin A 150u	EvergreenHealth	marketed	Neurotoxin; Acetylcholine release inhibitor	SNARE proteins (specifically SNAP-25)
Botulinum Toxin A (Botox )	Botulinum Toxin A (Botox )	Assistance Publique - Hôpitaux de Paris	marketed	Neurotoxin; acetylcholine release inhibitor	SNARE proteins (specifically SNAP-25); acetylcholine release machinery
botulinum type a	botulinum type a	Henry Ford Health System	marketed	Neurotoxin; botulinum toxin	SNARE proteins (synaptobrevin, SNAP-25, syntaxin); acetylcholine release machinery
intra-rectal botulinum toxin injections	intra-rectal botulinum toxin injections	University Hospital, Rouen	phase 3	Neuromuscular blocker	SNARE proteins
Botulinum Toxin Type A Injection [HG102]	Botulinum Toxin Type A Injection [HG102]	Hugel	phase 3	Neurotoxin; botulinum toxin preparation	SNARE proteins (synaptobrevin/VAMP); acetylcholine release machinery

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neurotoxin class)

Allergan · 2 drugs in this class
Aránzazu Vázquez Doce · 1 drug in this class
Ulthera, Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Incobotulinumtoxin A — Competitive Intelligence Brief. https://druglandscape.com/ci/incobotulinumtoxin-a. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing